Phosphodiesterase-4 Inhibition as a Potential Therapeutic Strategy in the Management of Obesity: a Review

Keyphrases

• Phosphodiesterase-4 (PDE4) 100%
• Obesity Management 100%
• Phosphodiesterase 4 Inhibitor 100%
• Potential Therapeutic Strategies 100%
• Obesity 50%
• Circulating Levels 25%
• Glycemic Control 25%
• Disease Management 25%
• Weight Loss 25%
• Weight Reduction 25%
• Glucagon-like 25%
• Therapeutic Efficacy 25%
• Energy Expenditure 25%
• Therapeutic Role 25%
• Systemic Inflammation Response Index 25%
• Impaired Glucose Metabolism 25%
• Chronic Inflammatory Diseases 25%
• Inflammatory Conditions 25%
• Lipolysis 25%
• Obesity Treatment 25%
• Morbid Obesity 25%
• Weight Reducing 25%
• Mitochondrial Biogenesis 25%
• Metabolic Disease 25%
• Body Weight Regulation 25%
• Pharmacological Approaches 25%
• Thermogenesis 25%
• Reducing Potential 25%
• Obesity Pathophysiology 25%
• Metabolic Effects 25%
• Metabolic Benefits 25%
• Steatotic Liver Disease 25%

Medicine and Dentistry

• Phosphodiesterase IV Inhibitor 100%
• Phosphodiesterase IV 100%
• Clinical Study 50%
• Pathophysiology 25%
• Serositis 25%
• Disease Management 25%
• Combination Therapy 25%
• Inflammatory Disorder 25%
• Liver Disease 25%
• Body Weight 25%
• Energy Expenditure 25%
• Glycemic Control 25%
• Glucose Metabolism 25%
• Lipolysis 25%
• Glucagon Like Peptide 1 25%
• Body Weight Loss 25%
• Water-Electrolyte Imbalance 25%
• Thermogenesis 25%
• Mitochondrial Biogenesis 25%
• Comorbidity 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Phosphodiesterase IV Inhibitor 100%
• Phosphodiesterase IV 100%
• Inflammation 50%
• Clinical Study 50%
• Pathophysiology 25%
• Combination Therapy 25%
• Inflammatory Disease 25%
• Liver Disease 25%
• Preclinical Study 25%
• Glucagon-Like Peptide-1 25%
• Comorbidity 25%
• Metabolic Disorder 25%